ExonHit looks for US inroads with new HQ (headquarters):
This article was originally published in Clinica
Executive Summary
ExonHit Therapeutics, the Paris, France company known for its proprietary gene profiling DATAS (differential analysis of transcript with alternative splicing) technology to develop pharmaceuticals and diagnostics, has opened a regional US headquarters office in Gaithersburg, Maryland. The US foothold will be used as a platform to develop alliances across its range of products and businesses, including blood based diagnostics. The company already has pharma-based agreements with Allergan and IDEC. The US operation will be under the overall control of ExonHit CEO Bruno Tocque, while Christina Hedberg will head up business development from the US office.